Stock Code: 600866 stock abbreviation: Star Lake Bioscience Co.Inc.Zhaoqing Guangdong(600866) No.: pro 2021-070 Star Lake Bioscience Co.Inc.Zhaoqing Guangdong(600866)
Suggestive announcement on stock trading risk
The board of directors and all directors of the company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and bear individual and joint liabilities for the authenticity, accuracy and completeness of its contents.
Important content tips:
Star Lake Bioscience Co.Inc.Zhaoqing Guangdong(600866) (hereinafter referred to as “the company” or “the listed company”) has a large cumulative increase in the closing price for four consecutive trading days on December 27, 28, 29 and 30, 2021. According to the data released by wind information, the Shanghai stock index rose by 0.03% from December 27 to 30, and the company’s stock rose by 44.68% over the same period, with a cumulative deviation from the Shanghai stock index of 44.65%. The short-term increase of the company’s stock was significantly higher than that of the Shanghai stock index over the same period, but there was no significant change in the company’s fundamentals, and there was no major information that should be disclosed. Please pay attention to the transaction risks in the secondary market, make rational decisions and invest prudently.
The company is mainly engaged in the R & D, production and sales of food additives, chemical APIs, pharmaceutical intermediates and feed additives. It provides production raw materials for food processing, pharmaceutical manufacturing, feed processing and other related enterprises. At present, the company does not produce intermediate products related to carbonic anhydride and ritonavir, and the main business and product structure have not changed significantly. According to the company’s self-examination and verification with the company’s controlling shareholders, as of the disclosure date of this announcement, there is no material information that should be disclosed but not disclosed, except for the matters disclosed by the company.
On December 27, 28 and 29, 2021, the cumulative deviation of the closing price of the company’s shares from the value exceeds 20%. The company has disclosed the announcement on abnormal fluctuation of Star Lake Bioscience Co.Inc.Zhaoqing Guangdong(600866) Stock Trading (Announcement No.: pro 2021-069) on December 30, 2021. On December 30, 2021, the company’s stock price rose again. In view of the large fluctuation of the company’s stock price in the short term, the company now explains the relevant matters and risks as follows. Please make rational decisions, pay attention to risks and invest prudently.
1、 Secondary market transaction risk prompt
The closing price of the company’s shares increased significantly in four consecutive trading days on December 27, 28, 29 and 30, 2021. According to the data released by wind information, the Shanghai stock index rose by 0.03% from December 27 to 30, and the company’s stock rose by 44.68% over the same period, with a cumulative deviation from the Shanghai stock index of 44.65%. The short-term increase of the company’s stock is seriously higher than that of the Shanghai stock index over the same period, and there may be a risk of speculation in the secondary market.
The turnover rate of the company’s shares on December 30 was 11.68%, higher than the average turnover rate of 8.61% in the previous five trading days; However, the fundamentals of the company have not changed significantly, and there is no major information that should be disclosed but not disclosed. Please pay attention to the transaction risks in the secondary market, make rational decisions and invest prudently.
2、 Relevant information concerned and verified by the company
(i) Production and operation
According to the company’s self inspection, the company’s current production and operation activities are normal, the daily operation has not changed significantly, and the internal production and operation order is normal.
（2） Major events
The company and the controlling shareholders have no material information that should be disclosed but not disclosed, including but not limited to major asset restructuring, share issuance, acquisition, debt restructuring, business restructuring, asset divestiture, asset injection, share repurchase, equity incentive, bankruptcy restructuring, major business cooperation, introduction of strategic investors and other major matters related to the company.
（3） Media reports, market rumors and hot concepts
The company did not find any media reports and market rumors that may have a significant impact on the company’s stock trading price, nor did it involve the concept of market hot spots.
（4） Other stock price sensitive information.
After verification, the controlling shareholders, directors, supervisors and senior managers of the company did not buy or sell the company’s shares during the abnormal fluctuation of this stock transaction.
3、 Relevant risk tips
(i) Ribavirin API is one of the company’s products and belongs to the raw materials of downstream pharmaceutical enterprises. The end use of its products is arranged by downstream enterprises. From January to September 2021, the operating revenue of ribavirin API was about 4.67 million yuan, accounting for less than 1% of the company’s total operating revenue, accounting for a small proportion of the company’s operating revenue, which had little impact on the company’s overall operating performance. The company has not invested in new production capacity of this product in recent years, and there is no significant change in customers at present.
（2） Sichuan Jiuling Pharmaceutical Technology Co., Ltd. (hereinafter referred to as “Sichuan Jiuling”), a wholly-owned subsidiary of the company, is engaged in the production of pharmaceutical intermediates by CMO. The downstream products are controlled by API and pharmaceutical enterprises. At present, the products have no patents, and the main customers are Chinese customers, and do not produce intermediates related to carbonic anhydride and ritonavir. In 2021, except for the upgrading of environmental protection facilities and some sporadic technical transformation projects, Sichuan Jiuling did not invest in new production lines, and its overall production scale has not changed at present. The top five customers in 2021 have not changed significantly compared with previous years.
（3） The company’s year-on-year performance decreased in the first three quarters of 2021. The company disclosed the third quarter report of 2021 on October 26, 2021. In the first three quarters of 2021, the operating revenue was 824883600 yuan, a year-on-year increase of 2.34%, and the net profit attributable to the shareholders of the listed company after deducting non recurring profits and losses was 72260100 yuan, a year-on-year decrease of 28.79%. Please pay attention to the investment risk.
4、 Relevant risk tips
The company reminds investors that the information disclosure media designated by the company are China Securities News, Shanghai Securities News, securities times, securities daily and the website of Shanghai Stock Exchange (www.sse. Com.. CN.), Relevant company information shall be subject to the announcement published on the above designated website and media. Please pay attention to the transaction risks in the secondary market, make rational decisions and invest prudently.
It is hereby announced.
Star Lake Bioscience Co.Inc.Zhaoqing Guangdong(600866) board of directors December 31, 2021
